Pancreatic cancer is one of the deadliest and most difficult-to-detect forms of cancer. It kills nearly half a million people annually and has a five-year survival rate of less than 15 percent. The main challenge is that there are no reliable tools to detect the disease at early stages,

Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following surgery in a small, early trial were stil

Pancreatic cancer remains one of the most challenging tumors to treat, partly because it is often discovered at advanced stages when the disease has already spread, or metastasized. About half of pancreatic cancer patients experience metastasis to the liver,

The PAC-MANN test was able to differentiate — 98% of the time — between the blood of someone with pancreatic cancer and the blood of someone who doesn’t have the disease. When used alongside the existing CA 19-9 test, it was able to diagnose early-stage pancreatic cancer with 85% accuracy.

The five-year survival rate of people diagnosed with pancreatic cancer is currently 13 percent. Two breakthroughs are bringing hope for successfully treating this malignancy.

Pancreatic cancer remains difficult to treat, and is responsible for around 8 percent of all cancer deaths.It also has one of the lower longterm survival rates with only about 13 percent of patients surviving more than five years.

Scientists at Oregon Health and Science University (OHSU) have developed a new blood test for pancreatic cancer, one of the most deadly forms of the disease. Tests showed up to 85% accuracy in detection,

Pancreatic cancer reprograms nerve cells to fuel its growth, but blocking these connections can shrink tumors and boost treatment effectiveness. Pancreatic cancer is closely linked to the nervous system,

A new assay rapidly detected pancreatic ductal adenocarcinoma and differentiated it from noncancer pancreatic diseases by measuring cancer-associated protease activity in a small amount of blood.

A vaccine for pancreatic cancer could serve as a promising new therapy. At Memorial Sloan Kettering Cancer Center (MSK) in New York, an experimental approach to treating the cancer with a ...

Thanks to decades of sustained, predictable federal investments and increases in pancreatic cancer research, the research community is at a [...] READ MORE